PAM50 (Prediction Analysis of Microarray 50) gene signatures are a second-generation multi-gene expression assay used for quantifying the mRNA expression of 50 genes, including ER, PR, and Her2. It is currently recognized in the industry as a molecular subtype classification method for breast cancer. This evidence concerns the gene ERBB2 and breast cancer.